NewsRx

Search our medical news database

Aphios Corporation

Aphios Corporation Awarded Japanese Patent for Phospholipid Nanosomes Technology Platform

Published in Cancer Weekly, June 10th, 2008

Aphios Corporation announced that it has been awarded a Japanese Patent No. 4,107,680, issued on April 11, 2008, for its phospholipid nanosomes technology platform for the encapsulation of hydrophobic drugs.

Phospholipid nanosomes are small, uniform liposomes manufactured utilizing SuperFluids(TM). SuperFluids(TM) are normally gases which, when compressed, exhibit enhanced solvation, penetration and expansive properties. These fluids are reverse-engineered to form phospholipid nanosomes for encapsulating and improving the delivery of protein therapeutics, vaccine antigens and sRNAi molecules as well as small molecule therapeutics and hydrophobic drugs such as...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook